Actively Recruiting
Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
Led by Sun Yat-sen University · Updated on 2025-04-02
20
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This a phase 1 study to evaluate the safety and preliminary efficacy of cisplatin combined with bortezomib in patients with recurrent or metastatic breast cancer.
CONDITIONS
Official Title
Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 18 years and above with confirmed recurrent or metastatic advanced breast cancer
- Availability of tumor specimens (formalin-fixed, paraffin-embedded or fresh pre-treated recurrent tumor tissue)
- Patients who have failed standard treatment in late-stage breast cancer
- At least one measurable lesion
- ECOG performance status of 0 to 2
- Estimated survival period of at least 12 weeks
- Adequate major organ function including blood counts and biochemical parameters within specified limits
- Women of childbearing age must have a negative pregnancy test within 7 days before enrollment and agree to use reliable contraception during and for 8 weeks after treatment
- Voluntary participation with good compliance and willingness to follow up
You will not qualify if you...
- Acute active hepatitis B or C infection
- Serious underlying diseases, comorbidities, or active infections
- Currently receiving other anti-tumor treatments
- History of epilepsy or epileptic conditions
- Pregnancy or breastfeeding
- Poor compliance or inability to undergo normal follow-up
- Allergy to study drugs
- Diagnosis of other malignant tumors within 5 years, except certain treated skin or cervical cancers or those with no current disease and untreated for at least 2 years
- Other conditions deemed by the researcher to affect study conduct or results
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China, 510000
Actively Recruiting
Research Team
Y
Yanxia Shi, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
PREVENTION
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here